News | June 07, 2022
NewAmsterdam Pharma shares new data from Phase 2b ROSE Study
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
C2i Genomics expands its global reach and brings the first whole-genome sequencing minimal residual disease test to India
To address the preventive & primary healthcare delivery gaps in India
The information center has been established with the aim of providing Fortis Healthcare’s world-class healthcare services accessible to the people of Tirupati.
Follows Zealand Pharma’s appointment of Adam Steensberg as CEO and decision to refocus strategy
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Subscribe To Our Newsletter & Stay Updated
